Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a pill replace the IV? new study tests oral ketamine with drug boosters

NCT ID NCT07462559

Not yet recruiting Knowledge-focused Sponsor: Helsinki University Central Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial in 12 healthy volunteers tests whether cannabidiol (CBD) and cobicistat (a drug that boosts other medications) can increase the amount of oral ketamine that reaches the bloodstream. Ketamine is used for treatment-resistant depression but is usually given by IV because oral doses are poorly absorbed. The study will measure drug levels and side effects over 11 hours after dosing. It is an early step toward possibly developing an effective oral ketamine treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ketamine, cannabidiol, cobicistat
What this could lead to
If successful, this could show that combining ketamine with cobicistat makes oral ketamine more reliable, potentially enabling a pill form for depression treatment.
What could go wrong
This is a very early, small study in 12 healthy people, not patients. It only measures drug levels and side effects, not depression outcomes. Results may not translate to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG-DRUG INTERACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-DRUG INTERACTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Department of Clinical Pharmacology

    Helsinki, Finland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.